About Us | Ascendis Pharma

Home About Us

Mission & Values Roadmap Company Snapshot

We are applying our innovative technology platform to build a leading, fully integrated global biopharmaceutical company

Mission & Values

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon^® technology to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs.

Patients

We strive to make meaningful improvements in patients’ lives. We make business decisions based on patient needs and we do our best every day to realize our products’ benefits for patients.

Science

We are driven by science and data. We are dedicated to being curious and diligent when innovating, developing and improving products and processes.

Passion

We are passionate about realizing our shared vision and goals. We trust each other’s strengths, and when we face challenges we remain optimistic and commit to working together as one team to achieve extraordinary results.

Algorithm for product innovation

Our unique approach to product innovation focuses on identifying unmet medical needs where a clinically validated parent drug or pathway is suitable to our TransCon technologies. We call this our “algorithm.” It helps us select and advance product candidates for our ever-growing pipeline.

Leveraging this strategic approach, we currently have a pipeline of three independent endocrinology rare disease product candidates in clinical development and we are advancing oncology as a second therapeutic area of focus. We continue to expand into new therapeutic areas to address unmet patient needs.

Our vision is to create new therapies focused on making a meaningful difference in patients’ lives.

STRATEGIC ROADMAP

Our roadmap for the future, Vision 3x3, encompasses where we are today and where we aim to be in 2025. It speaks to our aspirations – how we intend to multiply our success to address unmet patient needs. Our goal is to achieve sustainable growth through multiple approaches:

Grow our endocrinology rare disease pipeline

Create further growth of our endocrinology rare disease pipeline

Establish a global commercial presence for our endocrinology rare disease area

Advance a high-value oncology pipeline with one IND or similar filing each year

Create a third independent therapeutic area with a diversified pipeline

VISEN Pharmaceuticals

In 2018, VISEN Pharmaceuticals was formed by Ascendis Pharma with an investor syndicate led by Vivo Capital. Focusing on endocrinology, VISEN has received exclusive rights to develop and commercialize Ascendis Pharma's endocrinology rare disease therapies, including TransCon hGH, TransCon PTH and TransCon CNP in Greater China.